LCS
BIO icon

Levin Capital Strategies’s Bio-Rad Laboratories Class A BIO Stock Holding History

Levin Capital Strategies’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-847
Closed -$356K – 249
2022
Q4 		$356K Buy
+847
New +$342K 0.05% 149
2022
Q2 		– Sell
-500
Closed -$282K – 285
2022
Q1 		$282K Buy
+500
New +$301K 0.03% 219
2019
Q1 		– Sell
-569,205
Closed -$132M – 199
2018
Q4 		$132M Buy
569,205
+561,328
+7,126% +$151M 2.91% 11
2018
Q3 		$2.46M Buy
7,877
+3,414
+76% +$1.06M 0.04% 94
2018
Q2 		$1.29M Sell
4,463
-9,179
-67% -$2.53M 0.02% 122
2018
Q1 		$3.41M Buy
+13,642
New +$3.47M 0.06% 91
2017
Q1 		– Sell
-267,619
Closed -$48.8M – 309
2016
Q4 		$48.8M Sell
267,619
-110,893
-29% -$18.9M 0.84% 35
2016
Q3 		$62K Sell
378,512
-417,550
-52% -$63.4M 0.91% 28
2016
Q2 		$114M Buy
796,062
+33,600
+4% +$4.79M 2.05% 14
2016
Q1 		$104M Buy
762,462
+73,248
+11% +$9.62M 1.89% 17
2015
Q4 		$95.6M Buy
689,214
+60,059
+10% +$8.32M 1.68% 19
2015
Q3 		$84.5M Sell
629,155
-27,051
-4% -$3.89M 1.44% 24
2015
Q2 		$98.8M Buy
656,206
+249,275
+61% +$35.7M 1.46% 26
2015
Q1 		$55M Sell
406,931
-429,796
-51% -$53.3M 0.82% 35
2014
Q4 		$101M Sell
836,727
-196,154
-19% -$22.6M 1.52% 20
2014
Q3 		$117M Buy
1,032,881
+79,080
+8% +$9.37M 1.78% 14
2014
Q2 		$114M Sell
953,801
-2,068
-0.2% -$253K 1.76% 16
2014
Q1 		$122M Buy
955,869
+152,963
+19% +$19.6M 2.05% 15
2013
Q4 		$99.2M Sell
802,906
-61,328
-7% -$7.47M 1.6% 22
2013
Q3 		$102M Buy
864,234
+127,355
+17% +$15M 1.73% 19
2013
Q2 		$82.7M Buy
+736,879
New +$86.4M 1.49% 21

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Levin Capital Strategies's BIO Position: Q1 2023 in Review

Levin Capital Strategies sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2023, closing a stake of 847 shares — an estimated $356K sold.

Levin Capital Strategies first reported a position in BIO in Q2 2013 and held it in 21 quarters. The position peaked at $132M in Q4 2018. 505 funds tracked by Wall St. Rank hold BIO as of Q1 2023.

  • Levin Capital Strategies reported no remaining Bio-Rad Laboratories Class A position as of Q1 2023 after selling out during the quarter.
  • Levin Capital Strategies sold 847 Bio-Rad Laboratories Class A shares in Q1 2023, an estimated $356K.
  • Levin Capital Strategies first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 21 quarters.
  • Levin Capital Strategies's Bio-Rad Laboratories Class A position peaked at $132M in Q4 2018.
  • 505 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2023.

Based on Levin Capital Strategies's 13F filing for Q1 2023, filed 24 Apr 2023.